PT  - JOURNAL ARTICLE
AU  - James, Phillip
AU  - Stoddart, David
AU  - Harrington, Eoghan D
AU  - Beaulaurier, John
AU  - Ly, Lynn
AU  - Reid, Stuart W
AU  - Turner, Daniel J
AU  - Juul, Sissel
TI  - LamPORE: rapid, accurate and highly scalable molecular screening for SARS-CoV-2 infection, based on nanopore sequencing
AID  - 10.1101/2020.08.07.20161737
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.07.20161737
4099  - http://medrxiv.org/content/early/2020/10/30/2020.08.07.20161737.short
4100  - http://medrxiv.org/content/early/2020/10/30/2020.08.07.20161737.full
AB  - LamPORE™ is a rapid way of testing/screening large numbers of samples for the presence or absence of SARS-CoV-2, the virus causing COVID-19. It combines barcoded multi-target amplification, 15-minute barcoded library preparation and real-time nanopore sequencing. Starting with extracted RNA, results can be obtained from 12 samples in approximately an hour and from 96 samples in under 2 hours. High scalability is achieved by combinatorial barcoding.Competing Interest StatementAll authors are employees of Oxford Nanopore Technologies and are shareholders and/or share option holders.Funding StatementAll authors are employees of Oxford Nanopore Technologies and receive compensation and benefits from the companyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patient consent was not required as these were routinely collected samples and stored as per normal protocols used for clinical practice. They did not contain any cellular material and were therefore not subject to HTA. Therefore, as for assay development, using anonymised samples, no IRAS/ethics was required or sought. Sheffield Teaching Hospital NHS Foundation TrustAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe nucleotide sequences of the SARS-CoV-2 genomes used in the primer inclusivity and cross-reactivity analysis are available, upon free registration, from the GISAID database. https://www.gisaid.org/